{"organizations": [], "uuid": "f615d4a1a3b043a76e35dc701d45e27a9ee3e880", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180308.html", "section_title": "Archive News &amp; Video for Thursday, 08 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-fujian-cosunter-pharmaceutical-rec/brief-fujian-cosunter-pharmaceutical-receives-gmp-certificate-idUSL4N1QQ35F", "country": "US", "domain_rank": 408, "title": "BRIEF-Fujian Cosunter Pharmaceutical receives GMP certificate", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.907, "site_type": "news", "published": "2018-03-08T16:01:00.000+02:00", "replies_count": 0, "uuid": "f615d4a1a3b043a76e35dc701d45e27a9ee3e880"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-fujian-cosunter-pharmaceutical-rec/brief-fujian-cosunter-pharmaceutical-receives-gmp-certificate-idUSL4N1QQ35F", "ord_in_thread": 0, "title": "BRIEF-Fujian Cosunter Pharmaceutical receives GMP certificate", "locations": [], "entities": {"persons": [], "locations": [{"name": "beijing", "sentiment": "none"}], "organizations": [{"name": "gmp", "sentiment": "negative"}, {"name": "reuters) - fujian cosunter pharmaceutical co ltd", "sentiment": "neutral"}, {"name": "thomson reuters trust principles", "sentiment": "none"}, {"name": "fujian food and drug administration", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 8(Reuters) - Fujian Cosunter Pharmaceutical Co Ltd :\n* Says it received goods manufacture practice (GMP) certificate from Fujian Food and Drug Administration\n* Says certificate issued to adefovir dipivoxil manufactured by the company and the valid period is until Feb. 22, 2023\nSource text in Chinese: goo.gl/J3DEyk\nFurther company coverage: (Beijing Headline News)\nOur Standards: The Thomson Reuters Trust Principles.", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html", "https://goo.gl/J3DEyk"], "published": "2018-03-08T16:01:00.000+02:00", "crawled": "2018-03-09T14:46:39.002+02:00", "highlightTitle": ""}